Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent.

• 影响指数: 11.677
• 发表时间: Jul 2014
• 来源期刊: J Clin Microbiol
• DOI: 10.1128/JCM.00656-14
• PMID: 24759716
• 文章类型: Journal Article
• 中科院分区: Q1
• 方向: 医学
• 作者列表: Ross JE,Scangarella-Oman NE,Flamm RK,Jones RN

Mesh: Anti-Infective Agents / pharmacology; Gram-Negative Bacteria / drug effects; Gram-Positive Bacteria / drug effects; Humans; Microbial Sensitivity Tests / standards; Molecular Structure; Quality Control; Topoisomerase Inhibitors / pharmacology

Abstract

GSK2140944 is a novel bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens, including Gram-positive pathogens and methicillin-resistant Staphylococcus aureus. This quality control study was performed to establish ranges for selected control strains: S. aureus ATCC 29213 and ATCC 25923, Escherichia coli ATCC 25922, Haemophilus influenzae ATCC 49247, and Streptococcus pneumoniae ATCC 49619. The control ranges will be crucial for the accurate evaluation of GSK2140944 potency as it progresses through clinical trial development.